For decades, oncologists have looked to the disappearance of cancer cells after chemotherapy as a hopeful sign — a kind of biological promise that the worst has passed. A new multicenter study of nearly 400 women with hormone-receptor-positive breast cancer now complicates that promise, finding that while pathological complete response reliably predicts freedom from recurrence, it does not independently foretell longer life. The study invites medicine to reckon with the difference between a tumor's short-term silence and a patient's long-term survival, and to seek more nuanced guides in the mo
Complete tumor response predicts recurrence risk but not survival in hormone-positive breast cancer
Complete response prevented recurrence but not death
Mark
Why does it matter that complete response doesn't predict survival if it clearly prevents recurrence?
Mimi
Because recurrence and death are not the same thing. A patient can have cancer come back and still live for years—especially with hormone-positive disease, which often grows slowly. If we're using complete response to decide whether a treatment worked, we might be celebrating the wrong outcome.
Mark
So the chemotherapy is working, just not in the way we thought?
Mimi
Exactly. It's eliminating the tumor in the breast, which is real and measurable. But that doesn't mean it's extending life. Something else—maybe the hormone therapy that comes after, maybe the biology of the tumor itself—is what actually determines whether someone survives long-term.
Mark
What about the patients with low estrogen receptor expression? They're the ones achieving complete response.
Mimi
They're the ones whose tumors are chemotherapy-sensitive. But here's the puzzle: those same tumors, even when they disappear completely, don't translate into better survival. It suggests that chemotherapy sensitivity and long-term prognosis are measuring different things.
Mark
Does this mean neoadjuvant chemotherapy shouldn't be used in hormone-positive breast cancer?
Mimi
Not at all. It still prevents recurrence, which matters to patients. But it means we shouldn't oversell it as a survival cure. And it means we need better ways to predict who will actually benefit before we start treatment.
Mark
What would better prediction look like?
Mimi
The study suggests measuring estrogen receptor and Ki-67 more carefully. Those markers tell you something about tumor biology that complete response doesn't capture. You might be able to say: this patient's tumor is unlikely to respond to chemotherapy, so let's try something else. That's more useful than waiting to see if the tumor disappears.
Mark
How long do we need to follow these patients to know if complete response matters for survival?
Mimi
That's the question the authors are asking. Hormone-positive cancers can recur decades later. The current follow-up might not be long enough to see the full picture. We might need 10 or 15 years of data before we know whether complete response actually saves lives.
The Pulse
- Only one in five patients with HR-positive breast cancer achieved complete tumor elimination after chemotherapy — a sobering rate that exposes the limits of this treatment strategy for the most common breast cancer subtype.
- Patients who did achieve complete response were six to eight times less likely to see their cancer return, creating a powerful but incomplete picture of benefit.
- The critical tension emerges when survival is measured: complete response failed to independently predict whether patients actually lived longer, severing the assumed link between tumor disappearance and long-term survival.
- Tumor biology — specifically low estrogen receptor expression and high Ki-67 proliferation scores — proved to be the more reliable compass for predicting who would respond to chemotherapy at all.
- Researchers are now pointing toward longer prospective studies and more precise molecular profiling as the path forward, moving clinical decision-making away from a single binary outcome and toward a richer reading of each patient's disease.
For decades, oncologists have looked to the disappearance of cancer cells after chemotherapy as a hopeful sign — a kind of biological promise that the worst has passed. A new multicenter study of nearly 400 women with hormone-receptor-positive breast cancer now complicates that promise, finding that while pathological complete response reliably predicts freedom from recurrence, it does not independently foretell longer life. The study invites medicine to reckon with the difference between a tumor's short-term silence and a patient's long-term survival, and to seek more nuanced guides in the molecular character of the disease itself.
When a breast cancer patient receives chemotherapy before surgery, clinicians watch closely for one outcome above all: the complete disappearance of cancer cells in the surgically removed tissue. This pathological complete response has long been treated as a reliable harbinger of lasting benefit. A new study of 379 women with hormone-receptor-positive, HER2-negative breast cancer — the most common breast cancer subtype — now challenges that assumption in important ways.
The multicenter research, spanning patients treated between 2010 and 2025, tracked both recurrence-free and overall survival while also examining which tumor characteristics predicted complete response. Only 18.7 percent of patients achieved it. Those who did showed a striking reduction in recurrence risk — roughly six to eight times lower than those who did not — making complete response appear, at first glance, like a powerful prognostic tool.
But the picture shifted when researchers examined overall survival. Complete response no longer independently predicted whether patients lived longer. The same patients who had avoided recurrence did not demonstrate a statistically significant survival advantage, exposing a meaningful gap between two measures that oncologists have often treated as interchangeable.
The study also clarified which patients were most likely to respond to chemotherapy in the first place. Tumors with low estrogen receptor expression and high Ki-67 scores — indicating rapid cell division and less dependence on hormone signaling — were significantly more chemotherapy-sensitive. Conversely, high estrogen receptor expression, while associated with poor chemotherapy response, was linked to better long-term survival, suggesting these tumors follow a different biological logic.
The authors stop short of dismissing pathological complete response as a clinical marker, but they urge caution about its use as a measure of long-term benefit. Their findings point toward a future in which estrogen receptor quantification and proliferation profiling guide treatment decisions more precisely — and in which a single binary outcome gives way to a more textured understanding of each patient's disease.
When a breast cancer patient receives chemotherapy before surgery—a strategy called neoadjuvant treatment—doctors watch for a specific outcome: the complete disappearance of cancer cells in the tissue removed at operation. This outcome, known as pathological complete response, has long been treated as a reliable sign of good things to come. But a new study of nearly 400 patients challenges that assumption, at least for one major category of breast cancer.
Researchers at multiple centers examined 379 women with hormone-receptor-positive, HER2-negative breast cancer who received chemotherapy before surgery between 2010 and 2025. This subtype accounts for roughly two-thirds of all breast cancers and is generally considered less aggressive than other forms. The team looked at what happened to these patients over time, tracking both their recurrence-free survival and their overall survival. They also examined the tumor characteristics that predicted who would achieve complete response—that is, who would have no detectable cancer remaining after chemotherapy.
The results revealed a striking gap between two different measures of success. Only about one in five patients—18.7 percent—achieved complete pathological response. Those who did showed a dramatic reduction in recurrence risk. The hazard ratio for recurrence ranged from 0.13 to 0.17 across different statistical models, meaning patients with complete response were roughly six to eight times less likely to experience cancer recurrence during follow-up. By that measure, complete response looked like a powerful predictor of benefit.
But when the researchers examined overall survival—whether patients actually lived longer—the picture changed entirely. Complete response no longer predicted survival independently. The same patients who had avoided recurrence did not show a statistically significant survival advantage. This disconnect between recurrence-free survival and overall survival is the study's central finding, and it suggests that complete response may not be the prognostic gold standard that oncologists have assumed it to be in this population.
The research also identified which patients were most likely to achieve complete response in the first place. Tumors with lower estrogen receptor expression—10 percent or less—were significantly more likely to disappear completely with chemotherapy. Similarly, tumors with higher Ki-67 scores, a measure of how rapidly cells are dividing, were more responsive. These findings make biological sense: tumors that are less dependent on hormone signaling and more actively proliferating tend to be more chemotherapy-sensitive. Conversely, tumors with high estrogen receptor expression were much less likely to achieve complete response, suggesting they rely more heavily on hormone signaling than on rapid cell division.
When it came to predicting overall survival, different factors emerged as important. High estrogen receptor expression was associated with better long-term survival, not worse. Advanced spread to lymph nodes—specifically, involvement of three or more nodal stations—was the strongest independent predictor of worse survival. Younger age and high Ki-67 were associated with worse recurrence-free survival, a counterintuitive finding that may reflect the biology of aggressive tumors in younger women.
The authors conclude that complete pathological response remains a useful marker for identifying patients at lower risk of recurrence in the near term. But they caution against using it as a measure of long-term survival benefit, at least within the current follow-up period. They suggest that more precise measurement of estrogen receptor levels and proliferation markers might help identify which patients are most likely to benefit from chemotherapy before surgery. The findings point toward a future where treatment decisions rely less on a single binary outcome and more on a nuanced understanding of tumor biology and individual patient characteristics.
Notable Quotes
pCR may be a useful surrogate endpoint for recurrence-related outcomes but should be interpreted cautiously as a marker of long-term survival in this subgroup— Study authors
Want the full story?
Read the original at Nature ↗
Health & Medicine